Cargando…

Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model

BACKGROUND: The immunotherapy using dendritic cells (DCs) against different varieties of cancer is an approach that has been previously explored which induces a specific immune response. This work presents a mathematical model of DCs immunotherapy for melanoma in mice based on work by Experimental I...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo-Montiel, E., Chimal-Eguía, J. C., Tello, J. Ignacio, Piñon-Zaráte, G., Herrera-Enríquez, M., Castell-Rodríguez, AE.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469008/
https://www.ncbi.nlm.nih.gov/pubmed/26054860
http://dx.doi.org/10.1186/s12976-015-0007-0
_version_ 1782376584896839680
author Castillo-Montiel, E.
Chimal-Eguía, J. C.
Tello, J. Ignacio
Piñon-Zaráte, G.
Herrera-Enríquez, M.
Castell-Rodríguez, AE.
author_facet Castillo-Montiel, E.
Chimal-Eguía, J. C.
Tello, J. Ignacio
Piñon-Zaráte, G.
Herrera-Enríquez, M.
Castell-Rodríguez, AE.
author_sort Castillo-Montiel, E.
collection PubMed
description BACKGROUND: The immunotherapy using dendritic cells (DCs) against different varieties of cancer is an approach that has been previously explored which induces a specific immune response. This work presents a mathematical model of DCs immunotherapy for melanoma in mice based on work by Experimental Immunotherapy Laboratory of the Medicine Faculty in the Universidad Autonoma de Mexico (UNAM). METHOD: The model is a five delay differential equation (DDEs) which represents a simplified view of the immunotherapy mechanisms. The mathematical model takes into account the interactions between tumor cells, dendritic cells, naive cytotoxic T lymphocytes cells (inactivated cytotoxic cells), effector cells (cytotoxic T activated cytotoxic cells) and transforming growth factor β cytokine (TGF−β). The model is validated comparing the computer simulation results with biological trial results of the immunotherapy developed by the research group of UNAM. RESULTS: The results of the growth of tumor cells obtained by the control immunotherapy simulation show a similar amount of tumor cell population than the biological data of the control immunotherapy. Moreover, comparing the increase of tumor cells obtained from the immunotherapy simulation and the biological data of the immunotherapy applied by the UNAM researchers obtained errors of approximately 10 %. This allowed us to use the model as a framework to test hypothetical treatments. The numerical simulations suggest that by using more doses of DCs and changing the infusion time, the tumor growth decays compared with the current immunotherapy. In addition, a local sensitivity analysis is performed; the results show that the delay in time “ τ”, the maximal growth rate of tumor “r” and the maximal efficiency of tumor cytotoxic cells rate “aT” are the most sensitive model parameters. CONCLUSION: By using this mathematical model it is possible to simulate the growth of the tumor cells with or without immunotherapy using the infusion protocol of the UNAM researchers, to obtain a good approximation of the biological trials data. It is worth mentioning that by manipulating the different parameters of the model the effectiveness of the immunotherapy may increase. This last suggests that different protocols could be implemented by the Immunotherapy Laboratory of UNAM in order to improve their results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12976-015-0007-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4469008
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44690082015-06-17 Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model Castillo-Montiel, E. Chimal-Eguía, J. C. Tello, J. Ignacio Piñon-Zaráte, G. Herrera-Enríquez, M. Castell-Rodríguez, AE. Theor Biol Med Model Research BACKGROUND: The immunotherapy using dendritic cells (DCs) against different varieties of cancer is an approach that has been previously explored which induces a specific immune response. This work presents a mathematical model of DCs immunotherapy for melanoma in mice based on work by Experimental Immunotherapy Laboratory of the Medicine Faculty in the Universidad Autonoma de Mexico (UNAM). METHOD: The model is a five delay differential equation (DDEs) which represents a simplified view of the immunotherapy mechanisms. The mathematical model takes into account the interactions between tumor cells, dendritic cells, naive cytotoxic T lymphocytes cells (inactivated cytotoxic cells), effector cells (cytotoxic T activated cytotoxic cells) and transforming growth factor β cytokine (TGF−β). The model is validated comparing the computer simulation results with biological trial results of the immunotherapy developed by the research group of UNAM. RESULTS: The results of the growth of tumor cells obtained by the control immunotherapy simulation show a similar amount of tumor cell population than the biological data of the control immunotherapy. Moreover, comparing the increase of tumor cells obtained from the immunotherapy simulation and the biological data of the immunotherapy applied by the UNAM researchers obtained errors of approximately 10 %. This allowed us to use the model as a framework to test hypothetical treatments. The numerical simulations suggest that by using more doses of DCs and changing the infusion time, the tumor growth decays compared with the current immunotherapy. In addition, a local sensitivity analysis is performed; the results show that the delay in time “ τ”, the maximal growth rate of tumor “r” and the maximal efficiency of tumor cytotoxic cells rate “aT” are the most sensitive model parameters. CONCLUSION: By using this mathematical model it is possible to simulate the growth of the tumor cells with or without immunotherapy using the infusion protocol of the UNAM researchers, to obtain a good approximation of the biological trials data. It is worth mentioning that by manipulating the different parameters of the model the effectiveness of the immunotherapy may increase. This last suggests that different protocols could be implemented by the Immunotherapy Laboratory of UNAM in order to improve their results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12976-015-0007-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-09 /pmc/articles/PMC4469008/ /pubmed/26054860 http://dx.doi.org/10.1186/s12976-015-0007-0 Text en © Castillo-Montiel et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Castillo-Montiel, E.
Chimal-Eguía, J. C.
Tello, J. Ignacio
Piñon-Zaráte, G.
Herrera-Enríquez, M.
Castell-Rodríguez, AE.
Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title_full Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title_fullStr Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title_full_unstemmed Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title_short Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
title_sort enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469008/
https://www.ncbi.nlm.nih.gov/pubmed/26054860
http://dx.doi.org/10.1186/s12976-015-0007-0
work_keys_str_mv AT castillomontiele enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel
AT chimaleguiajc enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel
AT tellojignacio enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel
AT pinonzarateg enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel
AT herreraenriquezm enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel
AT castellrodriguezae enhancingdendriticcellimmunotherapyformelanomausingasimplemathematicalmodel